Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
Capricor’s BLA for Deramiocel received Priority Review in March 2025
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
The company’s largest center for medical device applications, serving the entire Asian market
This collaboration marks a significant milestone for Abluva as the company aims to deliver value and innovative solutions in agentic AI security
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Subscribe To Our Newsletter & Stay Updated
